参考文献/References:
[1] Uzdensky A B, Demyanenko SV,Bibov M Y. Signal transduction in human
cutaneous melanoma and target drugs[J]. Curr Cancer Drug Targets, 2013, 13(8):
843-866.
[2] Arozarena I, Wellbrock C. Overcoming resistance to BRAF inhibitors[J].
Ann Transl Med, 2017, 5(19): 387.
[3] Welsh S J, Rizos H, Scolyer R A, et al. Resistance to combination BRAF
and MEK inhibition in metastatic melanoma: Where to next? [J]. Eur J Cancer,
2016, 62:76-85.
[4] Yecies J L. Manning B D. mTOR links oncogenic signaling to tumor cell
metabolism[J]. J Mol Med, 2011, 89(3): 221-228.
[5] Shimobayashi M,Hall M N. Making new contacts: the mTOR network in
metabolism and signalling crosstalk[J]. Nat Rev Mol Cell Biol, 2014, 15(3): 155
-162.
[6] Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the
majority of malignant melanomas[J]. J Invest. Dermatol, 2008, 128(4): 980-987.
[7] Lasithiotakis KG, Sinnberg T W, Schittek B, et al. Combined inhibition
of MAPK and mTOR signaling inhibits growth, induce cell death, and abrogates
invasive growth of melanoma cells[J]. J. Invest. Dermatol, 2008, 128(8): 2013.
[8] Ruzzolini J, Peppicelli S, Andreucci E, et al. Everolimus selectively
targets vemurafenib resistant BRAF(V600E)melanoma cells adapted to low pH[J].
Cacer Lett, 2017(408):43-54.
[9] Thallinger C, Poeppl W, Pratscher B, et al. CCI-779 plus cisplatin is
highly effective against human melanoma in a SCID mouse xenotranplantation
model[J]. Pharmacology, 2007, 79(4): 207-213.
[10] Bundscherer A, Hafner C, Maisch T, et al. Antiproliferative and
proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell
lines[J]. Oncol Rep, 2008, 19(2): 547-553.
[11] 杨丹,陈晓明,谢立君等. 雷帕霉素的三氮唑新衍生物FIM-X13 对人胃癌细胞株
AGS的作用及机制的初步研究[J].中国生物技术杂志,2016, 11(3): 224-228.
[12] Cioczyk-Wierzbicka D, Zarzycka M, Gil D, et al. mTOR inhibitor
Everolimus-induced apoptosis in melanoma cells[J]. J Cell Commun Signal, 2019,
Mar 8.
[13] Laplante M and Sabatini D M. mTOR signaling in growth control and
disease [J]. Cell, 2012, 149(2): 274-293.
[14] Yip C K, Murata K, Walz T, et al. Structure of the human mTOR complex
I and its implications for rapamycin inhibition[J]. Molecular Cell, 2010, 38(5):
768-774.
[15] Choo AY, Yoon S, Kim S G, et al. Rapamycin differentially inhibits
S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation[J].
PNAS, 2008, 105(45):17414-17419.